43.11
Kodiak Sciences Inc stock is traded at $43.11, with a volume of 737.46K.
It is up +1.77% in the last 24 hours and up +71.68% over the past month.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
See More
Previous Close:
$42.36
Open:
$42.64
24h Volume:
737.46K
Relative Volume:
0.70
Market Cap:
$2.67B
Revenue:
-
Net Income/Loss:
$-229.97M
P/E Ratio:
-9.9713
EPS:
-4.3234
Net Cash Flow:
$-136.51M
1W Performance:
+6.10%
1M Performance:
+71.68%
6M Performance:
+263.18%
1Y Performance:
+1,958%
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KOD
Kodiak Sciences Inc
|
43.11 | 2.62B | 0 | -229.97M | -136.51M | -4.3234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences (KOD) price target increased by 56.62% to 56.71 - MSN
Trend Report: What is the Moat Score of Kodiak Sciences Inc2026 Intraday Action & Technical Confirmation Trade Alerts - baoquankhu1.vn
Stop Loss: How does Kodiak Sciences Inc compare to its peers2026 EndofYear Setup & Fast Gain Swing Alerts - baoquankhu1.vn
Kodiak Sciences Inc. (KOD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kodiak Sciences (KOD) climbs 75% on stellar clinical results - MSN
Kodiak Sciences Achieves Strong Gains with Positive GLOW2 Trial Results - timothysykes.com
Kodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In Focus - Yahoo Finance
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals - Yahoo Finance
Kodiak Q4 loss wider than expected, pipeline development in focus - MSN
Kodiak Sciences Insider Sold Shares Worth $1,197,488, According to a Recent SEC Filing - marketscreener.com
Kodiak climbs on late-stage trial win for diabetic retinopathy therapy - MSN
Kodiak Sciences | 10-K: FY2025 Annual Report - Moomoo
Kodiak Sciences (KOD) Is Up 9.8% After Wider Loss, Going Concern Note And BLA Acceleration - Sahm
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists - Sahm
Lifesci Capital Trims Earnings Outlook for Kodiak Sciences - National Today
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences - MarketBeat
Kodiak Sciences CFO Borgeson sells $1.2m in shares By Investing.com - Investing.com Canada
Kodiak Sciences CFO Borgeson sells $1.2m in shares - Investing.com
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan - Stock Titan
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
[144] Kodiak Sciences Inc. SEC Filing - Stock Titan
Point72 reports 609,806 shares in Kodiak (KOD) — 1.0% stake - Stock Titan
Kodiak Sciences Inc. (KOD) options chain - Yahoo Finance Singapore
Kodiak Sciences (KOD) Sees Decline as Stock Falls 8.7% - gurufocus.com
Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation - Moomoo
Kodiak Sciences Inc. (KOD) Latest Stock News & Headlines - Yahoo! Finance Canada
Fed Meeting: Can Kodiak Sciences Inc lead its sector in growthQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Kodiak Sciences 2025 Financial Update - AlphaStreet
Kodiak Sciences (KOD) Reports Positive Developments in Q4 Results - GuruFocus
Kodiak Sciences (KOD) Shares Surge Over 10% - GuruFocus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings - StocksToTrade
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings - TipRanks
Why Kodiak Sciences Stock Is Suddenly Surging - TipRanks
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Kodiak Sciences Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) outlines retinal pipeline and going-concern risk - stocktitan.net
Phase 3 win and 2027 cash runway for Kodiak Sciences (NASDAQ: KOD) - stocktitan.net
Kodiak Sciences Q4 net loss widens on higher R&D spending - TradingView
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Bitget
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million - TradingView
Kodiak Sciences (NASDAQ:KOD) Trading 8.3% HigherHere's Why - MarketBeat
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
Kodiak reports positive phase 3 data on tarcocimab for DR - Eyes On Eyecare
Kodiak Sciences stock hits 52-week highhere's why - MSN
MACD Signal: Can Kodiak Sciences Inc grow without dilution2026 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn
Kodiak Sciences Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8%Time to Sell? - MarketBeat
Kodiak Sciences: Road To $120 - Forbes
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing - AOL.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Sale |
39.92 |
30,000 |
1,197,488 |
183,316 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):